Scor investors’ bad year can still get worse
The author is a Reuters Breakingviews columnist. The opinions expressed are her own.
By Aimee Donnellan
LONDON, July 16 (Reuters Breakingviews) -Scor SCOR.PA investors must be wishing they had access to a time machine. It’s six years since the 3.5 billion euro French reinsurer fought off a hostile takeover from its domestic rival Covéa, which valued the company at 43 euros per share. In 2024 problems in its life and health unit, revealed on Tuesday, mean it’s now worth less than half that. And there could be further strife to come.
Covéa and Scor’s arm wrestle began in 2018 when Scor rejected a takeover from the French mutual insurer. In 2019 lawsuits alleged that while Covéa CEO Thierry Derez was sitting on Scor’s board, he used confidential information to advance his own bid. Covéa denied wrongdoing but said the “continued attacks and hostile tactics” made it drop its plans. Eventually, in 2021, Covéa agreed to sell its stake in Scor and vowed not to buy any of its former target’s shares for seven years.
That pact now looks unfortunate, given Scor’s headaches. On Tuesday, the company’s shares collapsed 26% to just 19 euros a share after CEO Thierry Léger flagged that it may have to book a 500 million euro net loss in the health unit. More worryingly, Scor said the dent to its life and health business will impact the company’s solvency which will now merely be above 200% of regulatory minimum requirements, compared to 209% at the end of last year.
Investors should have two concerns. One is that the life insurance goof – partly down to mistaken assumptions that slow Covid-era claims rates would persist – could have been avoided. The other is that Scor’s property and casualty division, which pays out claims on damage from hurricanes and other natural disasters and accounts for around half of Scor’s 19.4 billion euros of premiums, may also drain capital. After all, the tropical storm season is just beginning and could lead to big payouts. The risk is Scor’s solvency sinks below the foot of its targeted 185% to 220% range.
If so, Scor might have to raise equity to bolster its reserves. That sort of uncertainty means potential suitors like domestic giant Axa AXAF.PA or private equity firms may not fancy lobbing in an opportunistic bid to take advantage of the company’s share implosion – and Covéa can’t. How Scor investors must pine for 2018.
Follow @aimeedonnellan on X
CONTEXT NEWS
Shares in Scor fell 26% on July 16 after the French reinsurer cut guidance for its life and health (L&H) unit.
The unit’s second-quarter insurance service result (ISR), a measure of profitability, is expected to fall to a loss of about 400 million euros and the full-year ISR is expected to be significantly less than the 500 million euros guided before, Scor says.
As of 0956 GMT, Scor shares were trading at 19.8 euros, down 24%.
Graphic: Scor’s share price has fallen far below Covéa’s 2018 offer https://reut.rs/3Y08eNl
Editing by George Hay and Oliver Taslic
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
